Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Described herein are processes for the purification of viruses and compositions thereof.
Core Innovation
The disclosed subject matter concerns aseptic purification of large Coronaviridae virus particles. A ligand-activated solid-phase matrix has an inactive porous shell that excludes virus particles from its core while allowing smaller molecules, including impurities, to enter; separating the matrix produces a purified virus preparation. The partial content also identifies host cell proteins and host cell genomic DNA as impurities addressed by the disclosed purification.
The provided partial content does not include the background section, so the problem being solved is not explicitly described there. It reports impurity reduction and comparable virus yield in the described purification and identifies purified virus preparations as inputs to immunization compositions, including compositions directed against Coronaviridae infections. The disclosed subject matter centers on selective impurity capture and the resulting purified preparation.
Claims Coverage
The claim coverage encompasses three inventive features across two independent claims directed to the purification of Coronaviridae virus particles and the manufacture of an immunization composition.
Selective ligand-activated matrix
Both independent claims recite a solid-phase matrix with a ligand-activated core and an inactive porous shell. The shell excludes the virus particles from the core while allowing smaller molecules to enter.
Aseptic purification of Coronaviridae virus particles
Claim 1 covers purification of Coronaviridae virus particles using the selective matrix and production of a final virus preparation by separating the matrix from the particles. The claim specifies a matrix concentration [procedural detail omitted for safety] and requires aseptic performance of each step.
Manufacture of an immunization composition
Claim 12 covers use of the purified Coronaviridae virus preparation to obtain a sterile composition for immunization against a viral infection caused by a virus of that family. The claim specifies a matrix concentration [procedural detail omitted for safety] and requires aseptic performance of each step.
The independent claims cover selective matrix-based purification of Coronaviridae virus particles and, separately, manufacture of a sterile immunization composition containing the resulting purified preparation.
Stated Advantages
The provided summary reports reduced impurities alongside comparable virus yield.
Documented Applications
Manufacture of a composition for immunization against a viral infection caused by a virus of the Coronaviridae family.
Interested in licensing this patent?